Generation Bio $237 million at-the-market offering
The shares are listed on Nasdaq
Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering program by Generation Bio Co. of up to an aggregate amount of $237 million of its common stock. The common stock is listed on the Nasdaq Global Select Market under the symbol “GBIO.”
Based in Cambridge, Massachusetts, Generation Bio is innovating non-viral genetic medicines to provide durable, redosable treatments for potentially hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms that it believes will enable highly differentiated therapeutic applications.
The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate Tomer Magid. Partner David R. Bauer and associates Brette L. Trost and Gabrielle Mazero provided intellectual property advice. All members of the Davis Polk team are based in the New York office.